Down Syndrome (Trisomy 21)
14
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
14%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Qualitative Effects of AEF0217 in Down Syndrome People
AEF0217 in Participants With Down Syndrome
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Sleep Intervention and Quality of Life in Down Syndrome
The Neurocognitive Bases of Trust in Intellectual Disability
Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down Syndrome
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
Neuropsychological Evaluation in Intellectual Disability (ENDI)
Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project
JASPER Intervention in Down Syndrome
Cognitive Orientation to Daily Occupational Performance and Conductive Education Approaches on Down Syndrome
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker
Non-Invasive Determination of Fetal Chromosome Abnormalities